Literature DB >> 18793860

IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis.

Giovanni Frisullo1, Viviana Nociti, Raffaele Iorio, Agata Katia Patanella, Alessandro Marti, Marcella Caggiula, Massimiliano Mirabella, Pietro Attilio Tonali, Anna Paola Batocchi.   

Abstract

We evaluated the spontaneous IL17, IFNgamma and IL10 production by peripheral blood mononuclear cells from patients affected by clinically isolated syndromes (CIS) suggestive of multiple sclerosis (MS) both in acute phase and in remission, relapsing remitting MS (RRMS) both in relapse and in remission, not-relapsing secondary progressive MS (SPMS) and controls. We observed higher IL17 levels in CIS patients both in acute phase and in remission than in SPMS patients and controls. On the contrary no difference in IL17 production was observed among RRMS patients and CIS, SPMS patients and controls. IFNgamma levels were significantly higher in CIS patients in acute phase than in CIS and RRMS patients in remission, SPMS patients and controls. Moreover, we observed higher IFNgamma spontaneous production in relapsing RRMS patients than in remitting RRMS and SPMS patients and controls. IL10 levels were significantly higher in remitting CIS and in relapsing RRMS patients than in SPMS patients and controls. There was no difference in IFNgamma, IL10 and IL17 levels between SPMS patients and controls. Our data suggest that IL17 might play a crucial role mainly in the early phase of MS, while IFNgamma seems to be involved both in the early phase and in the following relapses of the disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18793860     DOI: 10.1016/j.cyto.2008.08.007

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  26 in total

1.  Transplantation of olfactory ensheathing cells promotes partial recovery in rats with experimental autoimmune encephalomyelitis.

Authors:  Jia Li; Weian Chen; Yu'an Li; Ying Chen; Zhangna Ding; Dehao Yang; Xu Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

2.  Immunomodulatory function of Treg-derived exosomes is impaired in patients with relapsing-remitting multiple sclerosis.

Authors:  Maryam Azimi; Mojdeh Ghabaee; Abdorreza Naser Moghadasi; Farshid Noorbakhsh; Maryam Izad
Journal:  Immunol Res       Date:  2018-08       Impact factor: 2.829

Review 3.  The role of peripheral immune cells in the CNS in steady state and disease.

Authors:  Marco Prinz; Josef Priller
Journal:  Nat Neurosci       Date:  2017-01-16       Impact factor: 24.884

Review 4.  T cells in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  J M Fletcher; S J Lalor; C M Sweeney; N Tubridy; K H G Mills
Journal:  Clin Exp Immunol       Date:  2010-10       Impact factor: 4.330

Review 5.  Single nucleotide polymorphisms in multiple sclerosis: disease susceptibility and treatment response biomarkers.

Authors:  Vera Pravica; Dusan Popadic; Emina Savic; Milos Markovic; Jelena Drulovic; Marija Mostarica-Stojkovic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

6.  Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters.

Authors:  Michelle Sexton; Eiron Cudaback; Rehab A Abdullah; John Finnell; Laurie K Mischley; Mary Rozga; Aron H Lichtman; Nephi Stella
Journal:  Inflammopharmacology       Date:  2014-08-19       Impact factor: 4.473

7.  Fingolimod modulates T cell phenotype and regulatory T cell plasticity in vivo.

Authors:  Margarita Dominguez-Villar; Khadir Raddassi; Ann Caroline Danielsen; Joseph Guarnaccia; David A Hafler
Journal:  J Autoimmun       Date:  2018-08-16       Impact factor: 7.094

Review 8.  Effector T Cells in Multiple Sclerosis.

Authors:  Belinda J Kaskow; Clare Baecher-Allan
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

Review 9.  Non-receptor tyrosine kinase signaling in autoimmunity and therapeutic implications.

Authors:  Sabrina Solouki; Avery August; Weishan Huang
Journal:  Pharmacol Ther       Date:  2019-05-11       Impact factor: 12.310

Review 10.  Immunopathology of multiple sclerosis.

Authors:  Calliope A Dendrou; Lars Fugger; Manuel A Friese
Journal:  Nat Rev Immunol       Date:  2015-08-07       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.